Loading...
XSHE
300676
Market cap2.66bUSD
Dec 05, Last price  
45.03CNY
1D
0.83%
1Q
-11.81%
IPO
108.47%
Name

BGI Genomics Co Ltd

Chart & Performance

D1W1MN
XSHE:300676 chart
P/E
P/S
4.87
EPS
Div Yield, %
0.22%
Shrs. gr., 5y
0.61%
Rev. gr., 5y
6.67%
Revenues
3.87b
-11.10%
794,839,3481,047,380,6461,131,981,8471,318,703,6231,711,498,2532,095,544,2712,536,406,1052,800,411,9368,397,230,0026,766,137,3157,046,132,0814,349,637,2503,866,920,764
Net income
-903m
L
81,734,191135,880,89728,120,733262,099,904332,690,944398,091,510386,645,517276,334,0182,090,285,2731,461,536,272802,765,40892,900,396-902,690,862
CFO
96m
-76.58%
72,488,80036,701,6000328,682,815234,073,624226,570,84714,687,326224,254,9613,602,692,5312,476,132,383136,378,792408,767,85195,722,825
Dividend
Jul 04, 20240.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2. The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.
IPO date
Jul 14, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT